Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download From Breakthrough to Blockbuster PDF full book. Access full book title From Breakthrough to Blockbuster by Donald L. Drakeman. Download full books in PDF and EPUB format.
Author: Donald L. Drakeman Publisher: Oxford University Press ISBN: 0195084004 Category : Biotechnology industries Languages : en Pages : 241
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Author: Donald L. Drakeman Publisher: Oxford University Press ISBN: 0195084004 Category : Biotechnology industries Languages : en Pages : 241
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Author: Donald L. Drakeman Publisher: Oxford University Press ISBN: 0197626300 Category : Science Languages : en Pages : 241
Book Description
Financial Times Business Top Title March 2022 How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries? Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.
Author: Gary P. Pisano Publisher: Harvard Business Press ISBN: 9781591398400 Category : Business & Economics Languages : en Pages : 278
Book Description
Why has the biotechnology industry failed to perform up to expectations? This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. It also provides prescriptions for companies, seeking ways to improve the industry's performance.
Author: Jie Jack Li Publisher: Oxford University Press ISBN: 0199737681 Category : Business & Economics Languages : en Pages : 238
Book Description
"This book uses the cases of several landmark drugs to discuss the history of the pharmaceutical industry, and discusses what could be next"--Provided by publisher.
Author: Barry Werth Publisher: Simon and Schuster ISBN: 0671510576 Category : Business & Economics Languages : en Pages : 480
Book Description
This inside account of Vertex, a start-up pharmaceutical company, conveys the exciting drama being played out in the pioneering and enormously profitable field of drug research. Vertex is dedicated to designing--atom by atom--a new life-saving immunosuppressant drug that has major implications for HIV research.
Author: James O'Keefe Publisher: Simon and Schuster ISBN: 1476706174 Category : Language Arts & Disciplines Languages : en Pages : 352
Book Description
In this hard-hitting look at the way media and government conspire to protect the status quo, a controversial ambush journalist shows readers what happens when a young citizen journalist challenges some of America's most powerful and protected organizations.
Author: Jen-shih Lee Publisher: World Scientific ISBN: 9813270446 Category : Technology & Engineering Languages : en Pages : 346
Book Description
This book is about the great innovations that the biomedical industry has had on improving the health and treating diseases of people and the incredible effort that scientists, engineers, technologists, mathematicians and physicians has invested in conceptualizing, producing and marketing the innovations. This rapidly growing industry is a knowledge intensive industry that is constantly generating, and adapting to, new technology. The innovations are the movers leading to the growth of the biomedical industry since 1960. However, its growth may be threatened by the lack of access to capital, a burdensome and uncertain regulatory environment, and lack of R&D innovation and productivity.It is written for students and professionals in science, technology, engineering, mathematics and medicine wanting to become a successful biomedical entrepreneur and to grow the biomedical industry. This book covers these four sectors of biomedical industries: medical technologies, healthcare information technology, pharmaceutic industry and biotech.Many innovations are employed throughout the book to make this book as a resource of use to help you invent, evaluate, develop and market your innovative products. Part I examines the education merits of biomedical engineers and teaches biomedical professionals to conceptualize their innovations and to assess whether their innovations could be manufactured and be wanted by patients. Part II will guide budding entrepreneurs to form the company and entrepreneurial team, to raise venture capital, to patent your innovative products, to obtain regulatory approval and to write your business plan. Other important aspects of company operations like financing, negotiations, leadership, manufacturing, marketing and globalization are covered in Part III. Two concluding chapters, with excerpts from leaders in community, education and industries, touch on the development, growth and investment of biomedical entrepreneurs on the delivery of better healthcare and economy to all people in the world.
Author: Françoise Simon Publisher: Simon and Schuster ISBN: 9780743222440 Category : Business & Economics Languages : en Pages : 360
Book Description
Two foremost marketing strategists combine their expertise in the first ever book to offer cutting-edge global strategies for marketing biotechnology. 20 charts & graphs.
Author: Sally Smith Hughes Publisher: University of Chicago Press ISBN: 0226359204 Category : Business & Economics Languages : en Pages : 231
Book Description
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.
Author: Donald L. Drakeman
Author: Donald L. Drakeman
Author: Donald L. Drakeman
Author: Gary P. Pisano
Author: Vicki KUNKEL
Author: Jie Jack Li
Author: Barry Werth
Author: James O'Keefe
Author: Jen-shih Lee
Author: Françoise Simon
Author: Sally Smith Hughes